• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by TherapeuticsMD Inc. (Amendment)

    3/23/22 4:17:37 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TXMD alert in real time by email
    SC 13D/A 1 smith-sc13da_032322.htm AMENDMENT TO FORM SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13D/A

    (Amendment No. 12)

     

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2(a)) UNDER THE

    SECURITIES EXCHANGE ACT OF 1934

     

    THERAPEUTICSMD, INC.

    (Name of Issuer)

    Common Stock, $0.001 Par Value Per Share

    (Title of Class of Securities)

    88338n 10 7

    (CUSIP Number)

    ROBERT J. SMITH

    13650 Fiddlesticks Blvd.

    Suite 202-324

    Ft. Myers, FL 33912

    (417) 849-1005

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

                  march 23, 2022             

    (Date of Event Which Requires Filing of This Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    EXPLANATORY NOTE: The Reporting Person(s) is filing this amendment to correct the aggregate number of shares beneficially owned due to incorrectly reporting securities twice (once as warrants and once as shares upon exercise of warrants), and to confirm that as of February 13, 2018, the Reporting Person(s) owned less than 5% of the Issuer's issued and outstanding shares of common stock.

     

     

     

     

     

    CUSIP No. 88338N 10 7

    Page 2 of 11 Pages

     

    1.

    Name of Reporting Persons.

     

    Robert J. Smith

    2.

    Check the Appropriate Box if a Member of a Group

    (a) □

    (b) □

    3.

     

    SEC Use Only

     

    4.

     

    Source of Funds

     

    PF – Personal Funds

    5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

    □

     

    6.

    Citizenship or Place of Organization

     

    United States

    Number of Shares

    Beneficially Owned

    by Each Reporting

    Person With

    7.

    Sole Voting Power

    23,103,292

    8.

     

    Shared Voting Power

    -0-

    9.

    Sole Dispositive Power

    23,103,292

    10.

    Shared Dispositive Power

    -0-

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    23,103,292

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares

    *

    13.

    Percent of Class Represented by Amount of Row (11)

     

    5.38%

    14.

    Type of Reporting Person

     

    IN

             

     

     

     

     

     

     

    CUSIP No. 88338N 10 7

    Page 3 of 11 Pages

     

    1.

    Name of Reporting Persons.

     

    Energy Capital, LLC, an entity solely owned by Robert J. Smith

    2.

    Check the Appropriate Box if a Member of a Group

    (a) □

    (b) □

    3.

     

    SEC Use Only

     

    4.

     

    Source of Funds

     

    PF – Personal Funds

    5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

    □

     

    6.

    Citizenship or Place of Organization

     

    United States

    Number of Shares

    Beneficially Owned

    by Each Reporting

    Person With

    7.

    Sole Voting Power

    11,000,000

    8.

     

    Shared Voting Power

    -0-

    9.

    Sole Dispositive Power

    11,000,000

    10.

    Shared Dispositive Power

    -0-

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,000,000

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares

    *

    13.

    Percent of Class Represented by Amount of Row (11)

     

    2.56%

    14.

    Type of Reporting Person

     

    OO

             

     

     

     

     

     

     

    CUSIP No. 88338N 10 7

    Page 4 of 11 Pages

     

    1.

    Name of Reporting Persons.

     

    Plato & Associates, LLC, an entity solely owned by Robert J. Smith

    2.

    Check the Appropriate Box if a Member of a Group

    (a) □

    (b) □

    3.

     

    SEC Use Only

     

    4.

     

    Source of Funds

     

    PF – Personal Funds

    5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

    □

     

    6.

    Citizenship or Place of Organization

     

    United States

    Number of Shares

    Beneficially Owned

    by Each Reporting

    Person With

    7.

    Sole Voting Power

    11,353,292

    8.

     

    Shared Voting Power

    -0-

    9.

    Sole Dispositive Power

    11,353,292

    10.

    Shared Dispositive Power

    -0-

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,353,292

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares

    *

    13.

    Percent of Class Represented by Amount of Row (11)

     

    2.64%

    14.

    Type of Reporting Person

     

    OO

             

     

     

     

     

     

     

    CUSIP No. 88338N 10 7

    Page 5 of 11 Pages

     

    1.

    Name of Reporting Persons.

     

    Jo Cee, LLC, an entity solely owned by Robert J. Smith

    2.

    Check the Appropriate Box if a Member of a Group

    (a) □

    (b) □

    3.

     

    SEC Use Only

     

    4.

     

    Source of Funds

     

    PF – Personal Funds

    5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

    □

     

    6.

    Citizenship or Place of Organization

     

    United States

    Number of Shares

    Beneficially Owned

    by Each Reporting

    Person With

    7.

    Sole Voting Power

    -0-

    8.

     

    Shared Voting Power

    -0-

    9.

    Sole Dispositive Power

    -0-

    10.

    Shared Dispositive Power

    -0-

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    -0-

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares

    *

    13.

    Percent of Class Represented by Amount of Row (11)

     

    0.00%

    14.

    Type of Reporting Person

     

    OO

             

     

     

     

    CUSIP No. 88338N 10 7

    Page 6 of 11 Pages

     

     

    Item 1.Security and Issuer

    The class of equity securities to which this Schedule 13D relates is the common stock, $0.001 par value, of TherapeuticsMD, Inc., a Nevada corporation ("Company" or "Issuer"). The address of the principal executive office of the Company is 6800 Broken Sound Parkway NW, Third Floor, Boca Raton, FL 33487.

    Item 2. Identity and Background.

    (a)

    Names: Robert J. Smith, Energy Capital, LLC ("Energy Capital"), Plato & Associates, LLC ("Plato") and Jo Cee, LLC ("Jo Cee"), entities solely owned by Mr. Smith (the "Reporting Persons"). 

    (b)

    Residence or Business Address of Reporting Persons:

     

    13650 Fiddlesticks Blvd., Suite 202-324, Ft. Myers, FL 33912.(c)       

    Present principal occupation or employment of Reporting Persons: Business development and investments.

    (d)

    During the last five years, the Reporting Persons have not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). 

    (e)

    During the last five years, the Reporting Persons have not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding violation with respect to such laws. 

    (f)

    Citizenship: Mr. Smith is a citizen of the United States of America.

     

    Item 3. Source and Amount of Funds or Other Consideration.

    PF-Personal Funds

     

    Acquisition of Shares of the Issuer by Conversion of Debt

     

    As previously reported, Energy Capital owned a convertible promissory note in the principal amount of $105,000 (the "Note"). On October 18, 2011, the Company and Energy Capital, on behalf of itself and its assigns, entered into a Debt Conversion Agreement to convert the Note into an aggregate of 10,000,000 shares (the "Converted Shares"). Energy Capital received 7,750,000 of the Converted Shares.

     

    As previously reported, on July 28, 2011, the Company sold a Senior Secured Promissory Note (the "Secured Note") to Plato & Associates, LLC ("Plato") in the amount of $500,000 and also entered into a Security Agreement under which the Company pledged all of its assets to secure the obligation. The Secured Note accrued interest at the rate of six percent (6%) per annum, was due on the one (1) year anniversary thereof, and was convertible into shares of the Company's Common Stock at the option of the Company. On June 19, 2012, in accordance with the terms thereof, the Company and Plato agreed to convert the Secured Note plus interest into 1,387,167 shares of the Company's Common Stock at $.038 per share.

     

     

     

    CUSIP No. 88338N 10 7

    Page 7 of 11 Pages

     

     

    Acquisition of Shares of the Issuer through Private Placement

     

    On September 26, 2012, the Company entered into a Securities Purchase Agreement with multiple investors (collectively, the "Investors") relating to the issuance and sale of the Company's Common Stock in a private placement except from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). At the closing on October 2, 2012 (the "Closing Date"), the Company sold an aggregate of 3,953,489 shares at $2.15 per share (the "Shares") for an aggregate purchase price of $8,500,001. Of those shares, Energy Capital, LLC purchased 1,141,658 shares for a purchase price of $2,454,564. As part of the Securities Purchase Agreement, the Company agreed to file a registration statement cover the resale of the Shares no later than 45 days from the Closing Date (the "Registration Statement"). The Company filed a Registration Statement on Form S-1 which was declared effective by the SEC on December 12, 2012.

     

    Acquisition of Shares of the Issuer by Exercise of Warrants

     

    The Company issued Plato two Common Stock Purchase Warrants (“Warrant(s)”); one for the purchase of 3,000,000 shares of the Company’s Common Stock at $2,00 per share (the "First Warrant"), and for the purchase of 500,000 shares of the Company’s Common Stock at $3.00 per share (the "Second Warrant"). Plato subsequently assigned 450,000 shares of the First Warrant. On April 10, 2017, Plato exercised its right purchase the remaining 2,550,000 shares under the First Warrant and 500,000 shares under the Second Warrant on a cashless basis by surrendering its right to receive an aggregate of 850,735 shares in lieu of the cash exercise price and was issued an aggregate of 2,199,265 shares of the Company's Common Stock. An explanation of the history of the Warrants follows: On June 19, 2012, the Company sold and issued a Secured Promissory Note (the "June 2012 Note") to Plato in the principal base amount of $2,344,719 (the "Principal Base Amount") pursuant to the terms of that certain Note Purchase Agreement of even date therewith. As consideration for the June 2012 Note, Plato surrendered the Remaining Debt as described above in the amount of $1,344,719 and loaned the Company an additional $1,000,000. The Principal Base Amount of the Note, plus any and all additional advances made to the Company thereafter (the "Aggregated Principal Amount"), together with accrued interest at the annual rate of six percent (6%), is due in one lump sum payment on February 24, 2014. The Company entered into a Security Agreement of even date therewith and pledged all of its assets, tangible and intangible, as further described therein. As an inducement for Plato to lend the $1,000,000 in additional funds to the Company, Plato receive five-year Common Stock Purchase Warrants ("Warrants") to purchase an aggregate of 3,500,000 Shares, which Warrants contain a cashless exercise provision. Plato received one Warrant for the purchase of 3,000,000 shares of the Company's Common Stock at an exercise price of $2.00 per share (the "First Warrant") and another Warrant for the purchase of 500,000 shares at an exercise price of $3.00 per share (the "Second Warrant"). These Warrants were subsequently assigned and/or exercised as mentioned hereinabove.

     

    The Company issued Plato a Common Stock Purchase Warrant ("Warrant') for the purchase of 122,743 shares of the Company's Common Stock at an exercise price of $0.407355 per share. On June 19, 2012, Plato exercised the Warrant for the purchase of all 122,743 shares. An explanation of the history of the Warrant follows: On February 24, 2012, the Company sold and issued a Secured Promissory Note (the "February 2012 Note") to Plato in the principal base amount of $1,357,110 (the "Principal Base Amount(s)") pursuant to the terms of that certain Note Purchase Agreement of even date therewith. The Principal Base Amount was comprised of surrendered promissory notes previously issued by the Company in the aggregated amount of $857,110 (collectively known as the "Prior Notes") and an additional $500,000 delivered to the Company on February 24, 2012. The Principal Base Amount of the Note, plus any and all additional advances made to the Company thereafter (the "Aggregated Principal Amount"), together with accrued interest at the annual rate of six percent (6%), was due in one lump sum payment twenty-four (24) months from the date of issuance of the Note. In connection with the February 2012 Note, Plato received a Warrant to purchase 3,950,000 Shares. At June 19, 2012, the Aggregated Principal Balance and accrued interest under the Note was $2,895,719. On June 19, 2012, Plato exercised its right to purchase 4,072,743 shares of the Company's Common Stock (122,743 at an exercise price of $0.407357 per share (as described in the paragraph above) and 3,950,000 at an exercise price of $0.38 per share). The Company agreed that Plato could exercise its rights to purchase all available shares under Warrants through the surrender of $1,551,000 in debt (the "Surrendered Debt"). The Surrendered Debt was comprised of all accrued interest through June 19, 2012 plus a portion of principal from the Note necessary to equal the Surrendered Debt. The Aggregate Principal Amount of the Note held by Plato after purchasing the Warrants with the Surrendered Debt is $1,344,719 (the "Remaining Debt").

     

     

     

    CUSIP No. 88338N 10 7

    Page 8 of 11 Pages

     

     

    Acquisition of Shares through Settlement of Demand Note

     

    On April 30, 2013, the Reporting Persons acquired 1,981,730 shares of the Company's common stock when he acquired Jo Cee, LLC, a Florida limited liability company, in exchange for and in settlement of a demand promissory note in the principal amount of $654,000. Upon the settlement, Mr. Smith became the sole member and manager of Jo Cee, LLC.

     

    Acquisition of Derivative Securities of the Issuer

     

    Common Stock Purchase Warrant ("Warrant")

     

    Warrants Received for Issuance of Credit Line; Exercise of Warrant

     

    On January 31, 2013, the Company requested and Plato agreed to the issuance of a $10 million revolving line of credit ("Revolving Credit Note"). Multiple payments may be requested by the Company and the maturity date of the Revolving Credit Note is February 24, 2014. As an inducement to Plato, the Company issued a six-year Warrant for the purchase of 1,250,000 shares of the Company's Common Stock at an exercise price of $3.20 with a cashless exercise provision. The shares underlying the Warrant vested on October 31, 2013 and the Warrant expires on January 31, 2019. On January 30, 2019, Plato exercised the Warrant on a cashless basis and was issued an aggregate of 471,184 shares.

     

    Current Ownership of Shares

     

    Subsequent to the acquisition of shares outlined above, the Reporting Persons purchased, sold, and/or transferred shares in public and private transactions, resulting in a current aggregate ownership of 23,103,292 shares.

     

     

     

     

    CUSIP No. 88338N 10 7

    Page 9 of 11 Pages

     

     

    Item 4.Purpose of Transaction.

    See Item 3 above.

     

    The Reporting Persons have no plans which relate to or would result in:

     

    (a)

    The acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer;

     

    (b)

    An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries;

     

    (c)

    A sale or transfer of a material amount of assets of the issuer or of any of its subsidiaries;

     

    (d)

    Any change in the present board of directors or management of the issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

     

    (e)

    Any material change in the present capitalization or dividend policy of the issuer;

     

    (f)

    Any other material change in the issuer's business or corporate structure, including but not limited to, if the issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940;

     

    (g)

    Changes in the issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person;

     

    (h)

    Causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

     

    (i)

    A class of equity securities of the issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

     

    (j)      

    Any action similar to any of those enumerated above.

     

    Item 5.Interest in Securities of the Issuer.

    (a)

    The Reporting Persons own (i) 750,000 shares held directly by Robert J. Smith, (ii) 11,353,292 shares beneficially owned through Plato and Associates, LLC, (iii) 11,000,000 shares beneficially owned through Energy Capital, LLC, and (iv) zero shares beneficially owned through Jo Cee, LLC, a limited liability company that was dissolved in May 2019.. The percentage of class for the Reporting Persons of 5.38% is based on 429,577,683 shares of common stock of TXMD currently outstanding. Mr. Smith exercises voting and dispositive power over all such shares.

     

     

     

     

    CUSIP No. 88338N 10 7

    Page 10 of 11 Pages

     

     

    (b)

    Mr. Smith has sole power to vote or direct the vote and sole power to dispose or to direct the disposition of the 23,103,292 shares of the Company's Common Stock owned directly or indirectly. (See Rows 7-10 of page 2 herein.)

     

    (c)

    Please see Item 3 above for the description of the transaction relative to the shares and derivative securities acquired by the Reporting Persons.

     

    (d)

    The Reporting Persons know of no other person who has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such shares or derivative securities.

     

    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of Issuer

     

    Except for as outlined herein, the Reporting Persons have no contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the issuer, including but not limited to transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

     

    Item 7.Material to be Filed as Exhibits.

     

    Exhibit No. Date of Document Description of Document
    10.0 06/19/12 Note Purchase Agreement(1)
    10.1 06/19/12 Security Agreement(1)
    10.2 06/19/12 Secured Promissory Note, form of(1)
    10.3 06/19/12 Common Stock Purchase Warrant, form of(1)
    10.4 09/26/12 Securities Purchase Agreement(2)
    10.5 01/31/13 Revolving Line Note(3)

    ____________________

    (1) Filed as an exhibit to the Company's Current Report on Form 8-K filed with the Commission on June 21, 2012, which report and exhibits are incorporated herein by reference.

    (2) Filed as an exhibit to the Company's Current Report on Form 8-K filed with the Commission on October 2, 2012, which report and exhibit are incorporated herein by reference.

    (3) Filed as an exhibit to the Company's Current Report on Form 8-K filed with the Commission on February 6, 2013, which report and exhibit are incorporated herein by reference.

     

     

     

     

    CUSIP No. 88338N 10 7

    Page 11 of 11 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Dated: March 23, 2022

    By: /s/ Robert J. Smith

           Robert J. Smith, as an individual, and as

           Sole Managing Member of

           Energy Capital, LLC,

           Plato and Associates, LLC, and

           Jo Cee, LLC

     

     

     

    Get the next $TXMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TXMD

    DatePrice TargetRatingAnalyst
    3/11/2022$3.00 → $2.50Buy
    HC Wainwright & Co.
    11/12/2021$4.00 → $3.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $TXMD
    Leadership Updates

    Live Leadership Updates

    See more
    • TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

      - Robust Strategic Alternatives Process Continues - TherapeuticsMD, Inc. (NASDAQ:TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women's healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Glickman as the Company's Interim Co-Chief Executive Officers and Co-Principal Executive Officers. Dr. Bernick and Mr. Glickman succeed Mr. Hugh O'Dowd as the Company's Chief Executive Officer. Prior to this appointment, Dr. Bernick, the Company's co-founder, served as Chief Scientific and Medical Officer, and Mr. Glickman served as Chief Business Officer. The Company also announced that the Board of Directors appointed The Honorable Tommy Thompson, w

      9/12/22 6:50:00 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

      Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences (NASDAQ:ATIS) where she oversaw the design and development of the world's first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Medtronic, and Inamed Corporation, was pivotal in raising over $350 million from t

      8/8/22 8:45:00 AM ET
      $CVM
      $HSTO
      $TXMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive Officer

      - Mr. O'Dowd to succeed Robert G. Finizio, effective on or before December 31, 2021 - - Mr. Finizio appointed Vice Chair of the Board - TherapeuticsMD, Inc. (NASDAQ:TXMD) (TXMD or the Company), an innovative, leading women's healthcare company, today announced key leadership changes, including the appointment of Hugh O'Dowd, the Company's current President, as the Company's Chief Executive Officer and member of the board of directors. Mr. O'Dowd will succeed Robert G. Finizio, the Company's Co-founder and current Chief Executive Officer, effective on or before December 31, 2021. Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors. "I wan

      11/11/21 6:45:00 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thompson Tommy G bought $326 worth of shares (325 units at $1.00), increasing direct ownership by 2% to 14,779 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/15/25 7:59:38 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Walker Marlan D bought $489 worth of shares (490 units at $1.00), increasing direct ownership by 0.67% to 73,639 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/15/25 7:59:22 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Walker Marlan D bought $1,994 worth of shares (2,303 units at $0.87), increasing direct ownership by 3% to 73,149 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/10/25 4:29:49 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TherapeuticsMD Announces Full Year 2024 Financial Results

      TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(2.3) million, or $(0.20) per basic and diluted common share, a decrease of $5.4 million, compared to net loss from continuing operations of $(7.7) million, or ($0.74) per basic and diluted common share, for 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $1.8 million during the year ended Dec

      3/27/25 4:05:00 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TherapeuticsMD Announces Third Quarter 2024 Financial Results

      TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(567) thousand, or $(0.05) per basic and diluted common share, compared to a net loss of $(1.4) million, or $(0.13) per basic and diluted common share, for the third quarter of 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $547 thousand for the third quarter of 2024, a

      11/12/24 4:05:00 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TherapeuticsMD Announces Second Quarter 2024 Financial Results

      TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(1.05) million, or $(0.09) per basic and diluted common share, compared to a net loss of $(2.4) million, or $(0.24) per basic and diluted common share, for the second quarter of 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $234 thousand for the second quarter of 2024, a

      8/12/24 4:05:00 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

      Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-6) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 12/28/2021. Application Category: NDA, Application Number: 210132, Application Classification: Efficacy

      12/29/21 7:23:57 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for IMVEXXY issued to THERAPEUTICSMD INC

      Submission status for THERAPEUTICSMD INC's drug IMVEXXY (SUPPL-2) with active ingredient ESTRADIOL has changed to 'Approval' on 11/16/2021. Application Category: NDA, Application Number: 208564, Application Classification: Labeling

      11/17/21 4:38:32 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

      Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-3) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 06/22/2021. Application Category: NDA, Application Number: 210132, Application Classification: Labeling

      6/24/21 5:13:50 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on TherapeuticsMD with a new price target

      HC Wainwright & Co. reiterated coverage of TherapeuticsMD with a rating of Buy and set a new price target of $2.50 from $3.00 previously

      3/11/22 6:31:06 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on TherapeuticsMD with a new price target

      HC Wainwright & Co. reiterated coverage of TherapeuticsMD with a rating of Buy and set a new price target of $3.00 from $4.00 previously

      11/12/21 6:03:07 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thompson Tommy G bought $326 worth of shares (325 units at $1.00), increasing direct ownership by 2% to 14,779 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/15/25 7:59:38 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Walker Marlan D bought $489 worth of shares (490 units at $1.00), increasing direct ownership by 0.67% to 73,639 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/15/25 7:59:22 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Walker Marlan D bought $1,994 worth of shares (2,303 units at $0.87), increasing direct ownership by 3% to 73,149 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/10/25 4:29:49 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by TherapeuticsMD Inc.

      SC 13G - TherapeuticsMD, Inc. (0000025743) (Subject)

      11/12/24 4:40:08 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by TherapeuticsMD Inc. (Amendment)

      SC 13D/A - TherapeuticsMD, Inc. (0000025743) (Subject)

      11/17/23 9:28:51 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by TherapeuticsMD Inc. (Amendment)

      SC 13D/A - TherapeuticsMD, Inc. (0000025743) (Subject)

      6/30/23 8:29:16 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    SEC Filings

    See more
    • SEC Form 10-Q filed by TherapeuticsMD Inc.

      10-Q - TherapeuticsMD, Inc. (0000025743) (Filer)

      5/13/25 4:37:27 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - TherapeuticsMD, Inc. (0000025743) (Filer)

      5/13/25 4:15:21 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by TherapeuticsMD Inc.

      10-K/A - TherapeuticsMD, Inc. (0000025743) (Filer)

      4/30/25 5:00:11 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    Financials

    Live finance-specific insights

    See more
    • TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

      - Mayne Pharma gains exclusive U.S. commercialization rights for TXMD's products and acquires certain assets - - TXMD received approximately $153.1 million at closing; portion of proceeds used to repay all outstanding indebtedness under Sixth Street facility and redeem all outstanding preferred equity - - TXMD is eligible to receive up to $30.0 million in milestone payments and a minimum of $42.6 million in royalty payments - TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women's healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-lis

      1/3/23 6:50:00 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TherapeuticsMD Announces Third Quarter 2022 Financial Results

      - Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the third quarter ended September 30, 2022. "Our products continue to be adopted by healthcare providers and patients, and we continue to believe that they represent a significant opportunity. Our prescriber bases grew, and we added around 1,500 new prescribers for ANNOVERA and around 1,600 for IMVEXXY. Total quarterly prescriptions for both products remained relatively stable compared to the second

      11/14/22 4:05:00 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TherapeuticsMD Announces Second Quarter 2022 Financial Results

      - Quarterly total net revenue of $28.6 million - - ANNOVERA® TRx of 9,329, an increase of 28% over Q2 2021 - - Conference call scheduled for 8:30 a.m. ET today - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the Second Quarter ended June 30, 2022. "We saw solid revenue growth during the quarter, with an increase of 24% over the prior year period, while also experiencing a 21% decrease in operating expenses. The U.S. Food and Drug Administration's recent approval of our supplemental new drug application for ANNOVERA has significantly enhanced our ability to meet demand for the product.

      8/15/22 6:50:00 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care